Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.84 USD
Change Today +0.24 / 6.67%
Volume 2.5M
IDRA On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

idera pharmaceuticals inc (IDRA) Snapshot

Open
$3.61
Previous Close
$3.60
Day High
$3.85
Day Low
$3.54
52 Week High
01/13/15 - $5.48
52 Week Low
10/10/14 - $1.94
Market Cap
452.6M
Average Volume 10 Days
1.9M
EPS TTM
$-0.47
Shares Outstanding
117.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IDERA PHARMACEUTICALS INC (IDRA)

Related News

No related news articles were found.

idera pharmaceuticals inc (IDRA) Related Businessweek News

No Related Businessweek News Found

idera pharmaceuticals inc (IDRA) Details

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for oncology and rare diseases in the United States. It uses two proprietary drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and gene silencing oligonucleotide (GSO) technology. The company’s lead drug candidate includes IMO-8400, which is in Phase 1/2 clinical trials for the treatment of Waldenström’s Macroglobulinemia, diffuse large B-cell lymphoma, and Duchenne muscular dystrophy, as well as in Phase 2 clinical trial for the treatment of dermatomyositis. Its products also comprise IMO-9200, a drug candidate in Phase 1 clinical trial for use in selected autoimmune disease indications; and IMO-2055/IMO-2125 that are in Phase 1/2 clinical trials for applications as immune therapies for the treatment of cancer. In addition, the company is developing GSOs to turn off the messenger RNA associated with disease causing genes. It has license and research collaboration agreement with Merck & Co. to research, develop, and commercialize vaccine adjuvants containing TLR7, TLR8, and TLR9 agonists in the fields of cancer, infectious diseases, and Alzheimer’s disease; and an agreement with Abbott Molecular Inc. for the development of an in vitro companion diagnostic test. Idera Pharmaceuticals, Inc. was founded in 1989 and is based in Cambridge, Massachusetts.

45 Employees
Last Reported Date: 03/12/15
Founded in 1989

idera pharmaceuticals inc (IDRA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $50.0K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $425.9K
President of Research and Director
Total Annual Compensation: $856.4K
Compensation as of Fiscal Year 2014.

idera pharmaceuticals inc (IDRA) Key Developments

Idera Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2015

Idera Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported alliance revenue of $34,000 against $3,000 a year ago. Loss from operations was $12,523,000 against $8,973,000 a year ago. Net loss applicable to common stockholders was $12,481,000 or $0.12 per basic and diluted share against $9,146,000 or $0.12 per basic and diluted share a year ago.

Idera Pharmaceuticals, Inc. Announces FDA Orphan Drug Designation for IMO-8400 for the Treatment of Diffuse B-Cell Lymphoma

Idera Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for IMO-8400, an antagonist of the endosomal Toll-like receptors (TLRs) 7, 8 and 9, for the treatment of diffuse large B-cell lymphoma (DLBCL). Idera is currently conducting a clinical trial of IMO-8400 in patients with relapsed or refractory DLBCL harboring MYD88 L265P oncogenic mutation. Preclinical studies have shown that in B-cell lymphomas characterized by the MYD88 L265P oncogenic mutation, including DLBCL, TLR signaling is over-activated, thereby enabling tumor cell survival and proliferation. As a TLR antagonist, IMO-8400 inhibits TLR signaling. The objectives of the trial are to evaluate the compound's safety, tolerability and clinical activity. The protocol includes three dose-escalation cohorts of IMO-8400 administered subcutaneously.

Idera Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 01:40 PM

Idera Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 01:40 PM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Vincent J. Milano, Chief Executive Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IDRA:US $3.84 USD +0.24

IDRA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IDRA.
View Industry Companies
 

Industry Analysis

IDRA

Industry Average

Valuation IDRA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3,636.9x
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2,980.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IDERA PHARMACEUTICALS INC, please visit www.iderapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.